Civilization Ventures

Civilization Ventures Research Investment Thesis Civilization Ventures is an operator-led biotech fund founded by serial founder and biotech entrepreneur Shahram Seyedin-Noor. The firm's investment thesis focuses on essential health innovations led by exceptional scientific founders—particularly young PhDs and postdocs from elite academic institutions. The firm believes that disruptive breakthroughs in life sciences come from foundational scientific research and that investor support should serve as "mentor capital" rather than replacing founder vision. The firm describes their approach as "founder-centric," with deep operational expertise from their own experience launching, building, and scaling biotech companies. They explicitly focus on overlooked opportunities in genomics, diagnostics, AI-in-biotech, and synthetic biology—areas where scientific rigor and novel technical approaches can create category-defining companies. Sector and Focus Areas Civilization Ventures has evolved from an initially genomics-focused fund into a broader biotech platform with depth across multiple innovation sectors: Primary Focus: Genomics & Diagnostics : Liquid biopsy technologies, ultra-sensitive diagnostics for early cancer detection, prenatal diagnostics, sequencing tools Synthetic Biology & Gene Therapies : Gene editing platforms, cell therapies, novel therapeutic modalities targeting genetic disease Digital Health & AI : AI-powered diagnostic tools, value-based care platforms, remote health monitoring, clinical workflow optimization AI in Biology : Machine learning applications for drug discovery, diagnostic AI, biomarker identification, computational biology tools Secondary Areas: Clean energy and climate solutions (planetary health impact) Healthcare infrastructure and enabling technologies The firm has demonstrated particular strength in backing transformative diagnostic and genetic medicine companies, as evidenced by their portfolio of exits and IPOs. Investment Stage and Check Size Civilization Ventures operates primarily in early-stage venture capital: Stage Preferences: Seed : Primary focus, $1M-$5M range for teams with early validation Series A : Secondary focus, $5M-$15M range for companies demonstrating product-market fit Growth/Follow-on : Selective Series B and C participation to support portfolio winners Check Size Range: $100K - $10M (from F4-OS data) Seed investments typically: $1M-$5M Larger rounds for strong portfolio momentum or strategic adds The firm has demonstrated ability to scale with larger opportunity funds, closing a Opportunity Fund with >$100M total AUM in 2023, enabling participation in later-stage rounds for proven portfolio companies. Lead Tendency Civilization Ventures demonstrates a strong lead bias : The founding team's operational backgrounds and deep scientific networks position them to lead early-stage rounds Their "mentor capital" approach—active involvement in founder development, scientific due diligence, and portfolio support—requires leading positions Portfolio data shows leadership on seed investments with expert technical teams and academic founders They actively co-lead with other founders-turned-VCs and value alignment on vision over pure capital provision Evidence from Recent Activity: Multiple 2024-2025 portfolio companies showing early investment stage Fluent Bio (acquired by Illumina, 2024), Omada Health (IPO 2025), and BillionToOne (IPO 2025) invested at seed/series A Fund Status and Recent Activity Current Fund Status: Actively deploying Fund Timeline: CV Fund I (2017) : Initial fund, now with multiple exits CV Fund II (2020) : $35M fund, in harvest phase with significant exits CV Opportunity Fund (2023) : >$100M total available capital, actively deploying for follow-ons and larger rounds Recent Notable Activity (2024-2025): Fluent Bio acquired by Illumina (2024) - Gene synthesis and analysis tools Omada Health IPO (NASDAQ: OMDA) - Chronic disease management, January 2025 BillionToOne IPO (NASDAQ: BLLN) - Liquid biopsy diagnostics, January 2025 Foresight Diagnostics acquired by Natera (2025) - Early cancer detection through liquid biopsy Historical Exits (Sampling): Rocket Pharma (NASDAQ: RCKT, 2018) Singular Bio (acquired by Invitae, 2019) Lemonaid Health (acquired by 23andMe, 2021) Rewrite Therapeutics (acquired by Intellia, 2022) The combination of recent IPOs and strategic acquisitions demonstrates the firm's track record of backing category-defining companies across diagnostics, digital health, and gene editing. Decision Process and Timeline Decision Structure: Partnership-driven with scientific due diligence committee The firm operates with: Core team : Shahram Seyedin-Noor (Founder + Managing Partner), Sonia Maryam Setayesh (Investment Partner), Nat Kolber (Scientist-in-Residence) Operational support : Matt Wheeler (CFO) Scientific advisors : 40+ Fellows and 21+ named Advisors including CEOs, professors, and industry leaders Decision Timeline: Likely 2-4 weeks for seed-stage decisions given: Founder-first, experienced team structure Deep technical due diligence capability (built-in scientific review) Relationship-driven sourcing through academic networks Weekly partnership meetings (inferred from active management style) Typical Flow: Sourcing through academic partnerships and founder networks (Boston, SF, international academic hubs) Initial technical/scientific evaluation (internal team + fellow network) Partnership decision meeting 2-3 week operational diligence with advisor network Warm Introduction Preference Warm introductions strongly preferred - The firm's model is built on: Deep academic and founder networks (40+ Fellows, 21+ Advisors) Relationship-driven sourcing from their mentor network Portfolio founder referrals and ecosystem partnerships No mention of cold application process in public materials Founders without warm introductions should: Apply through their Fellowship program to get on the radar Seek intros through portfolio CEOs, advisors, or academic connections Demonstrate deep scientific credentials and academic pedigree Team Composition Core Investment Team (5 members): Shahram Seyedin-Noor - Founder + Managing Partner Serial biotech founder and investor (12+ exits including Rewrite, Rocket, SingularBio, Lemonaid) Pomona College (Economics), Harvard JD Former CEO of Inspirna (cancer therapeutics), Former CFO/VP of NextBio (genomics software, acquired by Illumina) Sonia Maryam Setayesh, PhD - Investment Partner PhD from USC (single cell diagnostics, precision oncology) Published in Nature and Blood, patented precision medicine liquid biopsy test Former VP of Partnerships at Nucleate, VP of Biotech Connection LA Manages scientific due diligence and Fellowship program Nat Kolber, PhD - Scientist-in-Residence Stanford Bioengineering PhD candidate (synthetic biology, genetic medicines) Smith College (Biochemistry), experience at Broad Institute Former business development at Stanford's Office of Technology Licensing Kelcee Everrette, PhD - Associate (joined 2023) Harvard Biological and Biomedical Sciences PhD (precision genome editors, rare diseases) Harvard undergraduate (Biomedical Engineering) Focus: scientific due diligence and deal sourcing Matt Wheeler, CPA - CFO Extensive alternative investments background CFA Level 2 completed, CPA designation Former hedge fund auditor and venture fund administrator Fellowship Program: 40+ Fellows (32 PhDs, 9 MDs, 5 MBAs) from world-class institutions including Stanford, Harvard, MIT, Berkeley, Oxford, Cambridge, Caltech Advisor Network: 21+ named advisors including: Public company executives (Sean Duffy - Omada CEO, others) Leading academics (professors from NYU, UCSF, Stanford) Portfolio company founders and operators Industry veterans across genomics, diagnostics, therapeutics Geographic Presence: Global with hubs in: San Francisco (headquarters) Boston (East Coast science hub) Los Angeles (growing biotech cluster) London/UK (international expansion) Investment Preferences Founder Profile: PhD or MD from top-tier institutions (Stanford, Harvard, MIT, Berkeley, Cambridge, Oxford, Caltech) Scientific rigor and published research track record First-time or early-stage founder preferred (firm provides "mentor capital") Deep domain expertise in their field Integrity and determination in solving important problems Company Profile: Addressing significant healthcare or biological challenges Science-driven (not incremental improvements) Defensible IP from academic research Addressable market with clear pathway to scale Founders committed to long-term vision Business Model Preferences: B2B2C models (enabling companies, not direct consumer focus) Strong gross margins potential Capital-efficient early growth Geographic Scope: Primary: US (SF Bay Area, Boston, NYC) Secondary: Europe (London, other EU hubs), selective Asia What They Avoid: Pure consumer apps Incremental improvements without novel science Hardware-only plays without software defensibility Founders without strong academic credentials or shipped products Summary Civilization Ventures is a founder-led, science-driven biotech fund with exceptional track record in early-stage investment. Their operator-first mindset, deep technical team, and global academic networks enable them to identify exceptional scientific founders building category-defining companies. They provide "mentor capital"—operational guidance combined with patient venture capital—particularly valuable for PhD founders new to entrepreneurship. The firm's portfolio demonstrates pattern recognition: backing first-time founders from elite institutions who combine novel science with entrepreneurial determination. Their recent exit activity (2024-2025 IPOs, acquisitions) validates this model and positions them as leading investors in genomics, diagnostics, synthetic biology, and digital health. For founders: Civilization Ventures prioritizes founder credibility, scientific rigor, and academic excellence. They prefer warm intros through their networks but are also receptive to exceptional applications through their Fellowship program. Their value extends beyond capital—active mentorship and access to their network of Fellows and Advisors.